Grischa W.
- Country
- Germany
- Department
- Kreiskrankenhaus Sindelfingen-Böblingen, Interdisziplinäres Brustzentrum Böblingen
Research Overview
- Comparative Study of Sacituzumab Govitecan Versus Sacituzumab Govitecan Plus Pembrolizumab in Low-Risk Triple-Negative Early Breast Cancer
- Adjuvant Dynamic Marker-Adjusted Personalized Therapy: Ribociclib Plus Endocrine Therapy Versus Chemotherapy in HR+/HER2- Early Breast Cancer
- Phase III Evaluation of Sacituzumab Govitecan Versus Physician's Choice in HER2-Negative Breast Cancer with High Relapse Risk Post-Neoadjuvant Therapy
Data & Insights
Has run more than one trial at 57 of 230 partner sites.
Specializations
Breast Cancer Treatment Innovation
This investigator specializes in advancing treatment strategies for HER2-negative breast cancer and triple-negative breast cancer (TNBC), with particular attention to early-stage disease management.
- Novel therapeutic combinations
- Early-stage breast cancer interventions
- High-risk patient management
Their research explores innovative treatment approaches using targeted therapies and immunotherapy combinations.
Personalized Medicine Approaches
The investigator focuses on developing personalized treatment strategies for breast cancer patients, particularly in hormone receptor-positive (HR+) disease states.
- Dynamic marker-adjusted therapy
- Risk-stratified treatment selection
- Endocrine therapy optimization
Their work emphasizes tailoring treatments based on individual patient characteristics and disease markers.
Clinical Outcomes Research
The investigator studies disease-free survival outcomes across different breast cancer subtypes and treatment modalities.
- Long-term survival analysis
- Treatment comparison studies
- Risk assessment protocols
Their research evaluates the effectiveness of various therapeutic approaches in improving patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.